Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard

Pharmacol Res. 2007 May;55(5):392-9. doi: 10.1016/j.phrs.2007.01.014. Epub 2007 Jan 25.

Abstract

High-fat diets and oxidative damage may contribute to the development of type 2 diabetes. Hypolipidaemic drugs and antioxidants were supposed to prevent the development of the disease. In this study, we investigated preventive effects of fenofibrate (200 mg kg(-1)), vitamin C (30 mg kg(-1)), combination of both in mice induced by streptozotocin (35 mg kg(-1)) and soluble lard (15 ml kg(-1)). The results showed the mice demonstrated hyperglycaemia and hypercholesterolaemia, visceral fat accumulation, and a slight increase in liver glycogen/triglyceride and oxidative stress within 60 days of treatment. Fenofibrate enhanced insulin sensitivity, improved glycaemic control, lowered serum triglycerides, reduced body and visceral fat weights, and decreased liver glycogen/lipid levels but showed hepatotoxicity in the mice. Vitamin C neither itself prevented nor enhanced preventive effects of fenofibrate on glucose and lipid metabolism but partly attenuated the hepatotoxicity of fenofibrate. These results suggest that fenofibrate inhibit development of type 2 diabetes induced by high-fat diets and oxidative stress. However, here, vitamin C just can serve as an adjunct to fenofibrate therapy against its hepatotoxicity. In the future study, we should investigate if higher dosage of vitamin C or other antioxidants would enhance preventive effects of fenofibrate in type 2 diabetes.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antioxidants / pharmacology
  • Ascorbic Acid / pharmacology
  • Blood Glucose / drug effects
  • Chemical and Drug Induced Liver Injury
  • Cholesterol / blood
  • Diabetes Mellitus, Experimental / chemically induced
  • Diabetes Mellitus, Experimental / metabolism
  • Diabetes Mellitus, Experimental / physiopathology
  • Diabetes Mellitus, Experimental / prevention & control*
  • Diabetes Mellitus, Type 2 / chemically induced
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / prevention & control*
  • Dietary Fats
  • Drug Therapy, Combination
  • Fenofibrate / pharmacology*
  • Fenofibrate / therapeutic use
  • Fenofibrate / toxicity
  • Glycogen / metabolism
  • Hypercholesterolemia / chemically induced
  • Hypercholesterolemia / metabolism
  • Hypercholesterolemia / prevention & control
  • Hyperglycemia / chemically induced
  • Hyperglycemia / metabolism
  • Hyperglycemia / physiopathology
  • Hyperglycemia / prevention & control*
  • Hypoglycemic Agents / pharmacology*
  • Hypoglycemic Agents / therapeutic use
  • Hypoglycemic Agents / toxicity
  • Hypolipidemic Agents / pharmacology*
  • Hypolipidemic Agents / therapeutic use
  • Hypolipidemic Agents / toxicity
  • Insulin Resistance*
  • Intra-Abdominal Fat / drug effects*
  • Intra-Abdominal Fat / metabolism
  • Liver / drug effects
  • Liver / metabolism
  • Liver Diseases / metabolism
  • Male
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Oxidative Stress / drug effects
  • Streptozocin
  • Triglycerides / blood
  • Triglycerides / metabolism

Substances

  • Antioxidants
  • Blood Glucose
  • Dietary Fats
  • Hypoglycemic Agents
  • Hypolipidemic Agents
  • Triglycerides
  • Streptozocin
  • Glycogen
  • Cholesterol
  • Matrix Metalloproteinase 9
  • Ascorbic Acid
  • lard
  • Fenofibrate